Building on CD19 based therapy for relapse or refractory follicular lymphoma

Med · Published 2026-05-01 · DOI 10.1016/j.medj.2026.101101

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.medj.2026.101101

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• A single-cell solution to a transplant mystery · Med · 2026 · Same journal
• Five trials reshaping multiple myeloma · Med · 2026 · Same journal
• Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity · Med · 2026 · Same journal
• Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation · Med · 2026 · Same journal
• Resectability redefined: Lessons from quadruple therapy in HCC · Med · 2026 · Same journal
• Rethinking parenteral nutrition as supportive therapy for neonatal sepsis · Med · 2026 · Same journal
• Rewriting the sarcomere: Gene therapy approaches for hypertrophic cardiomyopathy from bench to bedside · Med · 2026 · Same journal
• Power and sample-size estimation in human microbiome research · Med · 2026 · Same journal
• Ethics of gene therapy · Med · 2026 · Same journal
• Impact of lead-in ADT on grade ≥3 neutropenia in patients with metastatic hormone-sensitive prostate cancer treated with triplet therapy · Med · 2026 · Same journal